Causaly for biotech teams

De-risk your programbefore someone else's diligence does

The science, the competitive landscape and the evidence against your target, every claim traceable to its source.

Your queries are encrypted. ISO 27001 certified.

Causaly Pipeline Graph: the drug landscape for TL1A, 39 drugs by phase.Causaly Research: the key evidence gaps for a program, each with its source.

Biotech teams using Causaly

Trusted by the world's leading biopharma companies

Where's your program?

Different challenges at different stages

What a team needs to know changes as a program moves from target to clinic. Causaly can help with the decision you're facing at a given moment, whether it's about core biology, preparing for an investor conversation, or building an evidence plan.

The question on your desk

Is this target worth our next six months, and what is the on-target risk?

What makes it hard
  • A small team covering biology outside each person's expertise
  • Targets that look strong on paper fail on on-target, off-disease effects
  • Human genetics, expression and safety evidence sit in different places
Teams at this stageManas AI
Candidate targets3 to assess
✓Human genetics✓Tissue expression✓On-target risk
How Causaly can help

The questions to anticipate at your next investor conversation

Typical questions and tasks real biotech teams use Causaly Research for.

Every competing asset on your target, by phase, modality and company, including the early entrants a quick search misses.

Example promptMap the drug landscape for TL1A (TNFSF15): every asset by phase, modality and company
Causaly Pipeline Graph: the drug landscape for TL1A, 39 drugs by phase, with HXN-1002 from Earendil Labs highlighted in Preclinical.
Customer story
“Companies live and die based on the identification and veracity of their targets.”
Dr. Siddhartha MukherjeeCo-founder, Manas AI

How Manas AI validates targets with Causaly

  • One evidence assessment for every candidate target, before resources are committed.
  • Human genetics, preclinical findings, phase 1 and 2 results, competitor activity and adverse effects graded by severity, in one structured view.
  • Used again later in the pipeline as a sanity check, feeding clinical signals back into target decisions.
Read the Manas AI case study
Show the work

See exactly where every answer comes from

  • Click any citation, read the sentence. The source opens on the highlighted passage the claim rests on.
  • The evidence against is shown, not hidden. Supporting and refuting findings sit side by side.
  • When the evidence isn't there, it says so. It names its assumptions and the gaps it couldn't close.
It held its hand up and said it didn't know… it was just actually quite refreshing.
Head of Bioinformatics, UK biotech
A Causaly answer with the cited paper open beside it, the supporting sentences highlighted in place.
How it compares

Built for science, measured against general AI

Same research questions, three tools. Causaly finds more of the evidence that matters and cites nothing off-topic.

76%
Recall of relevant primary + supporting evidence

vs. 42% for ChatGPT and 20% for Claude

95.6%
Factuality on scientific outputs

with 100% groundedness in the evaluation

0%
Topically irrelevant citations

vs. 7% for ChatGPT and 30% for Claude

Confidentiality

Your research stays yours

The target or mode of action you're investigating in stealth, the data you generate in your proof of concept: that's your IP. We treat it that way.

Is our data used to train models?
No. Your questions and documents are never used to train models.
Who can see our work?
Only the people you share it with.
Is our data encrypted?
Yes, in transit and at rest.
What security certifications does Causaly have?
Causaly is ISO 27001 certified, the international standard for information security.
Built for small teams

Your whole team, working from the same evidence

When the biologist, the clinician and the CEO start from the same sourced answers, the science, the clinical plan and the investor story stay consistent, and nobody repeats a search a colleague already ran.

Walk into your next investor meeting with the answers.

See your target, your landscape and the evidence against it, every claim sourced.

Start your free trial